marketing@medicilon.com
Compound druggability evaluation- Druggability refers to the properties of compounds with the potential to be developed into a marketed drug. Properties are defined by preliminary pharmacodynamic studies, early evaluation of pharmacokinetic properties, ADME and safety. Translational research helps to build a systematic R&D pathway from basic research, preclinical research and clinical efficacy evaluation to new drug manufacturing and the clinical application of innovative drugs. . The process of new drug development is lengthy, high-risk and high-reward. Medicilon provides druggability evaluation services to reduce the risk, time to market and cost. The druggability of new drug creation includes: druglikeness, physicochemical properties, biochemical properties, pharmacokinetics and toxicity.In the process of new drug development and clinical application, parameters of in-vivo processing of a compound (absorption, distribution, metabolism, excretion, ADME (toxic pharmacokinetics)) provide an important indicator of its druggability.
